OncoDNA
OncoDNA is a Belgium-based precision oncology company that provides CE-IVD cleared comprehensive genomic profiling kits (OncoDEEP, OncoSELECT), liquid biopsy assays, and the OncoKDM clinical interpretation platform to hospital laboratories, reference labs, and biopharma companies across Europe, the US, and the Middle East.
- Company typePrivate
- Founded2013
- HeadquartersGosselies, Belgium
- Headcount101–250
- GTM typeB2B
- OfferingServices
What OncoDNA does
OncoDNA S.A. is a Belgium-headquartered theranostic and genomic company specializing in precision medicine for cancer treatment, serving three primary customer segments: hospital and oncology-center clinicians, molecular pathology laboratories, and biopharma companies. The company's core offering is an integrated kit-plus-software ecosystem for comprehensive genomic profiling (CGP) of solid tumors and liquid biopsies, anchored by the CE-IVD cleared OncoDEEP Kit — a 638-gene DNA plus 20-gene RNA NGS panel covering SNVs, INDELs, CNVs, fusions, and genomic signatures (HRD, MSI, TMB) — and the OncoSELECT Kit for ctDNA liquid biopsy. These kits are bundled with OncoKDM, a cloud-based clinical interpretation platform whose knowledge database is updated nightly through automated and human-curated processes, providing actionable therapy recommendations, clinical trial matching, and reporting.
The company monetizes through four revenue streams: (i) one-time and multi-year kit sales to laboratories (OncoDEEP and OncoSELECT Kits), (ii) recurring annual subscriptions for the OncoKDM interpretation platform, (iii) professional services including send-away laboratory testing via its certified labs in Gosselies (Belgium) and Evry (France, via the 2020 IntegraGen acquisition), and (iv) pharma services spanning biomarker testing for clinical trials, precision patient enrollment, and OncoCDI Clinical Data Intelligence. Direct enterprise field sales target hospitals and reference laboratories, complemented by channel partnerships (Synlab, Berkshire and Surrey Pathology Services, NHS South East Genomic Medicine Service) and a UK partnership manager. The technology stack is platform-agnostic across Illumina, MGI DNBSEQ, and Element AVITI sequencers, with automation supported on Hamilton and Beckman Coulter liquid handlers.
Founded in 2012/2013 by Jean-Pol Detiffe, OncoDNA is venture-backed (cumulative funding approximately €35.7M including a €6.5M Series C in July 2023), operates from Gosselies (Belgium) with subsidiaries in Evry (France) and Valencia (Spain), and entered the US market in January 2021. Leadership includes CEO Dr. Bernard Courtieu (appointed January 2021), Chief Product Officer Koenraad Eycken, Chief Data Innovation Officer Gregori Ghitti, and Chairman François Blondel. The company has established clinical evidence including 92% of advanced solid cancer patients provided with treatment information and HRD validation against the PAOLA-1 cohort.
OncoDNA firmographics
Firmographics- Name
- OncoDNA
- Legal name
- OncoDNA S.A.
- Website
- https://oncodna.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- OncoDNA is a Belgium-based precision oncology company that provides CE-IVD cleared comprehensive genomic profiling kits (OncoDEEP, OncoSELECT), liquid biopsy assays, and the OncoKDM clinical interpretation platform to hospital laboratories, reference labs, and biopharma companies across Europe, the US, and the Middle East.
- Ownership category
- akta.pro rank
OncoDNA industry classification
Industry- Product category
- Precision Oncology Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)
- akta.pro secondary industries
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)
Keywords
Where OncoDNA is headquartered
LocationHeadquarters
- HQ city
- Gosselies
- HQ country
- Belgium
- HQ region
- Europe
Offices4 records
Markets served
OncoDNA business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- NGS Kit Sales (OncoDEEP Kit, OncoSELECT Kit): Sale of CE-IVD cleared library preparation and target enrichment kits to laboratories for in-house NGS-based comprehensive genomic profiling. Kits are sold with配套 software (OncoKDM) and support services.
- Clinical Testing Services: Send-away testing service using OncoDNA's own certified laboratory in Belgium for periods when customer lab workforce is unavailable or demand peaks. Covers both solid biopsy and liquid biopsy analysis.
- Software as a Service (OncoKDM): Subscription-based clinical interpretation software providing variant annotation, therapy recommendations, clinical trial matching, and reporting. Updated nightly with automated knowledge querying and human scientific team review.
- Pharma Services (Clinical Testing, Precision Enrollment, Clinical Data Intelligence): Services for biopharma companies including biomarker testing for clinical trials, patient matching to trials based on molecular profiles, and aggregated data insights for drug development.
- MRD Testing for Pharma: Molecular residual disease testing services for pharma clinical trial monitoring and companion diagnostics.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Multi-year contract | OncoDEEP Kit for laboratories |
| Subscription | Annual | OncoKDM software subscription |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels8 records
OncoDNA product offering
Product offeringCore offering
OncoDNA is a theranostic and genomic company offering a unified precision-oncology platform that combines CE-IVD NGS diagnostic kits (OncoDEEP, OncoSELECT, OncoXPLORE), CE-marked clinical decision support software (OncoKDM), and a clinical interpretation service (OncoSHARE) for laboratories, hospitals, and pharmaceutical companies. Its core business is comprehensive genomic profiling of solid tumors and hematological malignancies to guide therapy selection, while supporting pharma with biomarker discovery, clinical trial analytics, and companion diagnostic development.
Product overview
OncoDNA is a theranostic and genomic company offering a unified platform for precision oncology comprising diagnostic kits, laboratory services, and clinical decision support software. The core portfolio includes the OncoDEEP® Kit (638-gene solid tumor NGS panel with CE-IVD clearance), OncoSELECT® Kit (liquid biopsy ctDNA assay), and OncoXPLORE® (tumor-naïve profiling). These kits are complemented by the OncoKDM® interpretation platform with integrated knowledge database, OncoCDI® for clinical data intelligence, and OncoSHARE for ordering and sample management. For healthcare institutions, OncoDNA offers direct testing services (OncoDEEP, OncoSELECT, OncoFOLLOW for monitoring). Pharma partners access Clinical Testing, Precision Enrollment, and Knowledge-Driven Medicine services. The ecosystem integrates with Illumina, MGI, and Element AVITI sequencing platforms, with software connecting to Mercury analytics.
Differentiator
Problem solved
Functional benefit
Brands
- OncoDEEP: Comprehensive cancer biomarker test for solid tumors (solid biopsy) and the corresponding laboratory kit solution.
- OncoSELECT
- OncoXPLORE
- OncoKDM
- OncoCDI
- OncoFOLLOW
- OncoSHARE
Products and services
- OncoDEEP Kit
Quantifiable outcome
- 47% overall positive response to treatment in a private oncology practice following OncoDEEP molecular profiling guidance
- +2 more outcomes
Companies that use OncoDNA
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles3 records
OncoDNA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability5 records
Feature8 records
OncoDNA partnerships and signals
Strategic signalPartnerships
21 partnerships are on record, tiered core, supporting and minor.
- KU LeuvencoreOncoDNA and KU Leuven announced the commercial launch of OncoXPLORE, a tumor-naïve molecular profiling approach. OncoXPLORE enables comprehensive genomic profiling without prior tumor tissue characterization, developed through academic collaboration.
- MGI Tech (MGI)coreMGI and OncoDNA joined forces to offer laboratories a streamlined NGS workflow for implementing Comprehensive Genomic Profiling (CGP) using the OncoDEEP Kit on MGI's DNBSEQ platform. MGI provides the sequencing hardware while OncoDNA provides the kit and software. Validated on MGI DNBSEQ-G400 sequencer.
- NHS South East Genomic Medicine ServicecoreNHS South East Genomic Medicine Service transitioned to the OncoDEEP Kit solid tumour panel, enabling comprehensive genomic testing for oncology patients across the NHS South East region.
- Eli Lilly ItaliasupportingCollaboration between OncoDNA and Eli Lilly Italia to broaden access to biomarker testing for thyroid cancer patients, supporting patient access to targeted therapies.
- C2i GenomicscoreC2i Genomics and OncoDNA partnered to bring AI-powered liquid biopsy for cancer diagnostics across Europe. The partnership enables MRD (Molecular Residual Disease) testing across Europe using C2i Genomics' whole-genome sequencing platform and OncoDNA's laboratory network and CGP expertise.
- Berkshire and Surrey Pathology ServicessupportingBerkshire and Surrey Pathology Services and OncoDNA announced formation of a national tissue collection centre to facilitate private NGS testing across the UK.
- SynlabcoreOncoDNA and Synlab partnered to facilitate access to comprehensive biomarker testing for cancer therapy selection in Germany, leveraging Synlab's extensive pathology laboratory network.
- Bergonié InstitutesupportingBergonié Institute collaborated with OncoDNA to test the clinical utility of blood-and tissue-based biomarker tests in oncology, generating evidence for the clinical value of comprehensive genomic profiling.
- RadiomicsminorOncoDNA provided strategic support in Radiomics' prospective clinical trial SALMON, combining radiomics analysis with molecular profiling data.
- SOPHiA GENETICSsupportingOncoDNA teamed up with SOPHiA GENETICS to enable laboratories to establish data-driven medicine as a standard of care, combining genomic analysis with SOPHiA's analytics platform.
- European Cancer Patient CoalitionsupportingOncoDNA signed collaboration agreement with the European Cancer Patient Coalition on the 2020 personalised medicine awareness project to raise patient awareness of precision medicine.
- Bayer Saudi Arabia LLCsupportingCollaboration between Bayer Saudi Arabia LLC, OncoDNA, and Tamkin Al-Seha Medical to test cancer patients for rare NTRK mutations in Saudi Arabia, supporting Bayer's targeted therapy portfolio.
- Institut Jules BordetsupportingInstitut Jules Bordet collaborates with OncoDNA to explore biology of brain metastases using personalized liquid biopsy from cerebrospinal fluid, advancing understanding of metastatic brain cancer biology.
- Institut CuriesupportingOncoDNA and Institut Curie tested the clinical utility of personalized liquid biopsy in head and neck cancers, generating evidence for ctDNA-based monitoring in this cancer type.
- myNEOsupportingOncoDNA and myNEO joined forces to unlock the power of mRNA therapeutics by identifying tumor-specific antigens through combined genomic analysis to support personalized cancer vaccine development.
- American Hospital of ParissupportingAmerican Hospital of Paris and OncoDNA partnered to advance breast cancer patient management through comprehensive genomic profiling and precision medicine approaches.
- IlluminacoreOncoDEEP Kit is compatible with Illumina NextSeq 500/550, NextSeq 1000/2000, NovaSeq 6000, and NovaSeq X sequencers. Long-standing technology partnership for NGS sequencing platform integration.
- Twist BiosciencecoreTwist Bioscience provides hybrid capture technology used in OncoDEEP Kit for target enrichment. OncoDNA and Twist co-host educational webinars on NGS panel design and genomic signature identification. Collaboration enables optimized probe design for the 638-gene panel.
- Element BiosciencescoreOncoDEEP Kit has been validated on the Element AVITI System, expanding the range of compatible sequencing platforms for customers.
- Beckman Coulter (Automation)supportingBeckman Coulter automation solutions are supported for automated library preparation with OncoDEEP Kit, enabling laboratories to scale their CGP testing workflows.
- Hamilton (Automation)supportingHamilton automated platforms are supported for automated library preparation with OncoDEEP Kit, enabling high-throughput NGS workflows in laboratory settings.
Scale indicators5 records
Recent moves8 records
Expansion highlights7 records
OncoDNA competitors and assessment
Company assessmentDirect peers
- Foundation Medicine: Roche-owned leader in comprehensive genomic profiling for oncology via FoundationOne CDx and FoundationOne Liquid CDx. Directly comparable to OncoDNA's OncoDEEP and OncoSELECT offerings, with similar target customers (oncologists, hospitals, pharma) and overlapping NGS CGP panel content.
- Caris Life Sciences: US-based molecular profiling company offering comprehensive DNA/RNA sequencing plus AI-driven analytics (MI Profile, Caris Assure for MRD). Direct competitor in CGP and liquid biopsy with pharma services and biopharma partnerships analogous to OncoDNA's Precision Enrollment and OncoCDI.
- Tempus Labs: Precision medicine company combining NGS profiling (Tempus xT, xR, xF) with a large clinical and molecular database and pharma data analytics. Overlaps with OncoDNA in oncology CGP, pharma services, and clinical trial matching.
- Guardant Health: Specialist in liquid biopsy oncology testing (Guardant360 CDx, Reveal for MRD). Comparable to OncoDNA's OncoSELECT liquid biopsy and OncoFOLLOW MRD products, with similar pharma services and clinical trial focus.
- NeoGenomics: Oncology-focused clinical laboratory services company offering comprehensive NGS profiling (NeoTYPE panels), IHC, and pharma services. Comparable business model as both clinical testing service provider and kit/workflow enabler to hospital labs.
- Personalis: Cancer genomics company offering the ImmunoID NeXT platform for tumor profiling and the NeXT Personal MRD assay. Direct competitor in NGS CGP and liquid biopsy MRD with pharma/biopharma services comparable to OncoDNA's Precision Enrollment.
- SOPHiA GENETICS: Data-driven medicine platform combining NGS analytics with a global hospital network, including oncology applications. Comparable to OncoDNA's interpretation-software-plus-distributed-testing model; also an explicit collaboration partner of OncoDNA.
- Pillar Biosciences: NGS kit manufacturer focused on oncology and inherited disease panels sold to clinical laboratories. Direct competitor in the wet-lab kit layer of OncoDNA's OncoDEEP Kit offering.
Broad incumbents
- Agilent Technologies (Diagnostics): Large life sciences tools company with a cancer diagnostics franchise (including companion diagnostic development, NGS target enrichment via SureSelect, and pathology solutions). Broader portfolio than OncoDNA but overlapping in oncology molecular profiling reagents and CDx development.
Emerging players
- Inivata (now part of NeoGenomics): Liquid biopsy company with InVisionFirst-Lung and RaDaR MRD assays, now integrated into NeoGenomics. Comparable to OncoDNA's liquid biopsy ctDNA and MRD products in technology and target market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
OncoDNA social profiles
Digital presenceOncoDNA compliance and trust
Trust signalCompliance3 records
OncoDNA financial estimates
Financial estimateRevenue estimate
Valuation estimate
OncoDNA leadership team
Management profileNumber of profiles
Profiles9 records
OncoDNA subsidiaries and ownership
Company hierarchySubsidiaries1 record
OncoDNA funding detail
Funding detailFunding overview
Funding rounds2 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OncoDNA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OncoDNA
What does OncoDNA do?
OncoDNA is a theranostic and genomic company offering a unified precision-oncology platform that combines CE-IVD NGS diagnostic kits (OncoDEEP, OncoSELECT, OncoXPLORE), CE-marked clinical decision support software (OncoKDM), and a clinical interpretation service (OncoSHARE) for laboratories, hospitals, and pharmaceutical companies. Its core business is comprehensive genomic profiling of solid tumors and hematological malignancies to guide therapy selection, while supporting pharma with biomarker discovery, clinical trial analytics, and companion diagnostic development.
Is OncoDNA a public or private company?
OncoDNA is a private company. It is classified as venture growth investor backed and is currently operating.
When was OncoDNA founded?
OncoDNA was founded in 2013. It employs 101 to 250 people.
Where is OncoDNA based?
OncoDNA is headquartered in Gosselies, Belgium, in the Europe region.
How does OncoDNA make money?
Five revenue lines are on record. NGS Kit Sales (OncoDEEP Kit, OncoSELECT Kit) is the primary driver. The others are clinical Testing Services, software as a Service (OncoKDM), pharma Services (Clinical Testing, Precision Enrollment, Clinical Data Intelligence) and MRD Testing for Pharma.
Who are OncoDNA's main competitors?
Direct peers on record are Foundation Medicine, Caris Life Sciences, Tempus Labs, Guardant Health, NeoGenomics, Personalis, SOPHiA GENETICS and Pillar Biosciences. Agilent Technologies (Diagnostics) is listed as a broad incumbent. Inivata (now part of NeoGenomics) is listed as an emerging player.
Does OncoDNA have an API?
No public API is recorded for OncoDNA.
What industry is OncoDNA in?
OncoDNA's product category is Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 621511 and its SIC code is 8071.